Timing & benefit of CRT-IO in black & elderly patients with stage III NSCLC
Автор: VJOncology
Загружено: 2025-09-08
Просмотров: 30
Описание:
John Varlotto, MD, Marshall University, Huntington, WV, comments on outcomes in elderly and black patients with stage III non-small cell lung cancer (NSCLC) treated with chemo-radiation (CRT) and immunotherapy (IO). Overall survival benefit was maintained regardless of IO timing was reported, even when initiated 42 days post-CRT. Elderly patients benefited similarly to younger patients, and black patients derived greater benefit, despite underutilization in both groups, emphasizing the need to expand IO use in underrepresented populations. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
